Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models

Clinical Cancer Research

Volumn 6, Issue 3, 2000, Pages 998-1007

  Middlemas, David S ^a   Stewart, Clinton F ^a   Kirstein, Mark N ^a   Poquette, Catherine ^a   Friedman, Henry S ^b   Houghton, Peter J ^a   Brent, Thomas P ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE; GUANINE DERIVATIVE; PROTEIN P21; PROTEIN P53; TEMOZOLOMIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER REGRESSION; CHILDHOOD CANCER; CONTROLLED STUDY; DRUG SENSITIVITY; GENE EXPRESSION; GENE FUNCTION; GENE INDUCTION; GENE REPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SOLID TUMOR; TUMOR CLASSIFICATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BASE PAIR MISMATCH; BRAIN NEOPLASMS; CARRIER PROTEINS; CELL DIVISION; CHILD; DACARBAZINE; DNA REPAIR; DNA-BINDING PROTEINS; FEMALE; HUMANS; MICE; MICE, INBRED CBA; MUTS HOMOLOG 2 PROTEIN; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; NEUROBLASTOMA; NUCLEAR PROTEINS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PHENOTYPE; PROTO-ONCOGENE PROTEINS; RHABDOMYOSARCOMA; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034017285     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Bleehen, N. M., Newlands, E. S., Lee, S. M., Thatcher, N., Selby, P., Calvert, A. H., Rustin, G. J., Brampton, M., Stevens, M. F. Cancer Research Campaign Phase II trial of temozolomide in metastatic melanoma. J. Clin. Oncol., 13: 910-913, 1995.
2. Bower, M., Newlands, E. S., Bleehen, N. M., Bada, M., Begent, R. J., Calvert, A. H., Colquhoun, I. Lewis, P., Brampton, M. H. Multicentre CRC Phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother. Pharmacol., 40: 484-488, 1997.
3. Newlands, E. S., Stevens, M. F. G., Wedge, S. R., Wheelhouse, R. T., Brock. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat. Rev., 23: 35-61, 1997.
4. 6 alkylation in the mechanism of cytotoxicity of imidazotetrazines. Biochem. Pharmacol., 36: 457-462, 1987.
5. Wedge, S. R., Porteus, J. K., May, B. L., and Newlands, E. S. Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro. Br. J. Cancer, 73: 482-490, 1996.
6. 6-alkylguanine-DNA alkyltransferase attenuates triazene-induced cytotoxicity and tumor cell immunogenicity in murine L1210 leukemia. Cancer Res., 55: 6231-6236, 1995.
7. Branch, P., Aquilina, G., Bignami, M., and Karran, P. Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature (Lond.), 362: 652-654, 1993.
8. Tentori, L., Lacal, P. M., Benincasa, E., Franco, D., Faraoni, I., Bonmassar, E., and Graziani, G. Role of wild-type p53 on the antineoplastic activity of temozolomide alone or combined with inhibitors of poly(ADP-ribose) polymerase. J. Pharmacol. Exp. Ther., 285: 884-893, 1998.
9. Kolodner, R., Biochemistry and genetics of eukaryotic mismatch repair. Genes Dev., 10: 1433-1442, 1996.
10. Thibodeau, S. N., French, A. J., Roche, P. C., Cunningham, J. M., Tester, D. J., Lindor, N. M., Moslein, G., Baker, S. M., Liskay, R. M., Burgart, L. J., Honchel, R., and Halling, K. C. Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res., 56: 4836-4840, 1996.
11. Liu, L., Markowitz, S., and Gerson, S. L., Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res., 56: 5375-5379, 1996.
12. 6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide. Mol. Pharmacol., 52: 249-258, 1997.
13. D'Atri, S., Tentori, L., Lacal, P. M., Graziani, G., Pagani, E., Benincasa, E., Zambruno, G., Bonmassar, E., and Jiricny, J. Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol. Pharmacol., 54: 334-341, 1998.
14. Houghton, P. I., Cheshire, P. J., Hallman, J. D., Lutz, L., Friedman, H. S., Danks, M. K., and Houghton, J. A. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol, 36: 393-403, 1995.
15. Houghton, P. J., Cheshire, P. J., Hallman, J. C., Bissery, M. C., Mathieu-Boue, A., and Houghton, J. A. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10(4-[1-piperidino]-1-piperidino)-carboxyloxy-camptothecin against human tumor xenografts: Lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res, 53: 2823-2829, 1993.
16. Thompson, J., Zamboni, W. C., Cheshire, P. J., Lutz, L., Luo, X., Li, Y., Houghton, J. A., Stewart, C. F., and Houghton, P. J. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin Cancer Res., 3: 423-431, 1997.
17. Zamboni, W. C., Stewart, C. F., Thompson, J., Santana, V., Cheshire, P. J., Richmond, L. B., Liu, X., Houghton, J. A., and Houghton, P. J. The relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J. Natl Cancer Inst., 90: 505-511, 1998.
18. Hochberg, Y., and Tamhane, A. Multiple Comparison Procedures, pp. 94-96. New York: John Wiley & Sons, 1987.
19. Shen, F., Decosterd, L. A., Gander, M., Leyvraz, S., Biollaz, J., and Lejeune, F. Determination of temozolomide in human plasma and urine by high-performance liquid chromatography after solid-phase extraction. J. Liquid Chromatogr. B, 667: 291-300, 1995.
20. Newlands, E. S., Blackledge, G. R. P., Slack, J. A., Rustin, G. J. S., Smith, D. B., Stuart, N. S. A., Quarterman, C. P., Hofman, R., Stevens, M. F. G., Brampton, M. H., and Gibson, A. C. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br. J. Cancer, 65: 287-291, 1992.
21. Reid, J. M., Stevens, D. C., Rubin, J., and Ames, M. M. Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following the administration of temozolomide to patients with advanced cancer. Clinical Cancer Res., 3: 2393-2398, 1997.
22. Yeh, K. C., and Kwan, K. C. A comparison of numerical integrating algorithms by trapezoidal. Lagrange, and spline approximation. J. Pharmacokin. Biopharm., 6: 79-98, 1978.
23. Bradford, M. M. A rapid and sensitive method for the quantitation of of microgram quantities of protein using the principle of protein-dye binding. Anal. Biochem., 72: 248-254, 1976.
24. Thottassery, J. V., Zambetti, G. P., Arimori, K., Schuetz, E. G., and Schuetz, J. D. p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. Proc. Natl. Acad. Sci. USA, 94: 11037-11042, 1997.
25. Devineni, D., Klein-Szanto, A., and Gallo, J. M. Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470. Cancer Res., 56: 1983-1987, 1996.
26. Stevens, M. F. G., Hickman, J. A., Langdon, S. P., Chubb, D., Vickers, L., Stone, R., Baig, G., Goddard, C., Gibson, N. W., Slack, J. A., Newton, C., Lunt, E., Fizames, C., and Lavelle, F. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 3981), a novel drug with potential as an alternative to dacarbazine. Cancer Res., 47: 5846-5852, 1987.
27. 14C-temozolomide following oral administration to patients with advanced cancer. Clinical Cancer Res., 5: 309-317, 1999.